Z Squared Inc. (COEP) Form 10-Q — May 14, 2026
Z Squared Inc. (formerly Coeptis Therapeutics Holdings, Inc.) completed a reverse acquisition with Z Squared, Inc. on April 24, 2026, pivoting its primary business from biopharmaceuticals to digital asset mining. The company spun out substantially all of its biopharmaceutical operations, retaining only its interest in GEAR Therapeutics, Inc., while adopting the ticker ZSQR on Nasdaq.
Key figures
- Revenue
- 113771
- Total Debt
- 100000
- Cash Position
- 0
- Deal Value Usd
- 22000000
- Shares Outstanding
- 6553996
- Accumulated deficit
- 113870346
- Skycore max consideration
- 22000000
- Skycore power capacity mw
- 42
- Skycore base consideration
- 18000000
- Post merger shares outstanding
- 51431493
- Convertible note default amount
- 100000
Price after filing
1 day: 0.0%7 days: -17.1%30 days: +10.8%
Close on the filing date to close N calendar days later (from $9.84). Historical, not a forecast.
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.